BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 18065961)

  • 41. Antibody-based detection of ERG rearrangement-positive prostate cancer.
    Park K; Tomlins SA; Mudaliar KM; Chiu YL; Esgueva R; Mehra R; Suleman K; Varambally S; Brenner JC; MacDonald T; Srivastava A; Tewari AK; Sathyanarayana U; Nagy D; Pestano G; Kunju LP; Demichelis F; Chinnaiyan AM; Rubin MA
    Neoplasia; 2010 Jul; 12(7):590-8. PubMed ID: 20651988
    [TBL] [Abstract][Full Text] [Related]  

  • 42. TMPRSS2- driven ERG expression in vivo increases self-renewal and maintains expression in a castration resistant subpopulation.
    Casey OM; Fang L; Hynes PG; Abou-Kheir WG; Martin PL; Tillman HS; Petrovics G; Awwad HO; Ward Y; Lake R; Zhang L; Kelly K
    PLoS One; 2012; 7(7):e41668. PubMed ID: 22860005
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Protocols for Studies on TMPRSS2/ERG in Prostate Cancer.
    Pakula H; Linn DE; Schmidt DR; Van Gorsel M; Vander Heiden MG; Li Z
    Methods Mol Biol; 2018; 1786():131-151. PubMed ID: 29786791
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Genetic interaction between Tmprss2-ERG gene fusion and Nkx3.1-loss does not enhance prostate tumorigenesis in mouse models.
    Linn DE; Bronson RT; Li Z
    PLoS One; 2015; 10(3):e0120628. PubMed ID: 25780911
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Heterogeneity of ERG expression in prostate cancer: a large section mapping study of entire prostatectomy specimens from 125 patients.
    Tsourlakis MC; Stender A; Quaas A; Kluth M; Wittmer C; Haese A; Graefen M; Steurer S; Simon R; Korbel J; Weischenfeldt J; Huland H; Sauter G; Schlomm T; Minner S
    BMC Cancer; 2016 Aug; 16():641. PubMed ID: 27530104
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Detection of TMPRSS2-ERG Fusion Transcript in Biopsy Specimen of Prostate Cancer Patients: A Single Centre Experience.
    Trifunovski A; Dimovski A; Dohcev S; Stavridis S; Stankov O; Saidi S; Gjorgjievska M; Popov Z
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2020 Jun; 41(1):5-14. PubMed ID: 32573479
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer.
    Winnes M; Lissbrant E; Damber JE; Stenman G
    Oncol Rep; 2007 May; 17(5):1033-6. PubMed ID: 17390040
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer.
    Hermans KG; Boormans JL; Gasi D; van Leenders GJ; Jenster G; Verhagen PC; Trapman J
    Clin Cancer Res; 2009 Oct; 15(20):6398-403. PubMed ID: 19825963
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Characterization of stage-specific tumor progression in TMPRSS2-ERG (fusion)-driven and non-fusion-driven prostate cancer in GEM models.
    Raina K; Kant R; Prasad RR; Kandhari K; Tomar M; Mishra N; Kumar R; Fox JT; Sei S; Shoemaker RH; Chen Y; Maroni P; Agarwal C; Agarwal R
    Mol Carcinog; 2022 Jul; 61(7):717-734. PubMed ID: 35452553
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Loss of the NKX3.1 tumorsuppressor promotes the TMPRSS2-ERG fusion gene expression in prostate cancer.
    Thangapazham R; Saenz F; Katta S; Mohamed AA; Tan SH; Petrovics G; Srivastava S; Dobi A
    BMC Cancer; 2014 Jan; 14():16. PubMed ID: 24418414
    [TBL] [Abstract][Full Text] [Related]  

  • 51. N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer.
    Pflueger D; Rickman DS; Sboner A; Perner S; LaFargue CJ; Svensson MA; Moss BJ; Kitabayashi N; Pan Y; de la Taille A; Kuefer R; Tewari AK; Demichelis F; Chee MS; Gerstein MB; Rubin MA
    Neoplasia; 2009 Aug; 11(8):804-11. PubMed ID: 19649210
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues.
    Tu JJ; Rohan S; Kao J; Kitabayashi N; Mathew S; Chen YT
    Mod Pathol; 2007 Sep; 20(9):921-8. PubMed ID: 17632455
    [TBL] [Abstract][Full Text] [Related]  

  • 53. ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer.
    Hoogland AM; Jenster G; van Weerden WM; Trapman J; van der Kwast T; Roobol MJ; Schröder FH; Wildhagen MF; van Leenders GJ
    Mod Pathol; 2012 Mar; 25(3):471-9. PubMed ID: 22080055
    [TBL] [Abstract][Full Text] [Related]  

  • 54. TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate.
    Guo CC; Dancer JY; Wang Y; Aparicio A; Navone NM; Troncoso P; Czerniak BA
    Hum Pathol; 2011 Jan; 42(1):11-7. PubMed ID: 21040948
    [TBL] [Abstract][Full Text] [Related]  

  • 55. TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate.
    Danila DC; Anand A; Sung CC; Heller G; Leversha MA; Cao L; Lilja H; Molina A; Sawyers CL; Fleisher M; Scher HI
    Eur Urol; 2011 Nov; 60(5):897-904. PubMed ID: 21802835
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antibody-independent targeted quantification of TMPRSS2-ERG fusion protein products in prostate cancer.
    He J; Sun X; Shi T; Schepmoes AA; Fillmore TL; Petyuk VA; Xie F; Zhao R; Gritsenko MA; Yang F; Kitabayashi N; Chae SS; Rubin MA; Siddiqui J; Wei JT; Chinnaiyan AM; Qian WJ; Smith RD; Kagan J; Srivastava S; Rodland KD; Liu T; Camp DG
    Mol Oncol; 2014 Oct; 8(7):1169-80. PubMed ID: 25266362
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [PCA3 AND TMPRSS2:ERG GENES EXPRESSION IN BIOPSIES OF BENIGN PROSTATE HYPERPLASIA, INTRAEPITHELIAL NEOPLASIA, AND PROSTATE CANCER].
    Mikhaylenko DS; Perepechin DV; Grigoryeva MV; Zhinzhilo TA; Safronova NY; Efremov GD; Sivkov AV
    Urologiia; 2015; (5):46-50. PubMed ID: 26859937
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Complex patterns of ETS gene alteration arise during cancer development in the human prostate.
    Clark J; Attard G; Jhavar S; Flohr P; Reid A; De-Bono J; Eeles R; Scardino P; Cuzick J; Fisher G; Parker MD; Foster CS; Berney D; Kovacs G; Cooper CS
    Oncogene; 2008 Mar; 27(14):1993-2003. PubMed ID: 17922029
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Concurrent TMPRSS2-ERG and SLC45A3-ERG rearrangements plus PTEN loss are not found in low grade prostate cancer and define an aggressive tumor subset.
    Hernández S; Font-Tello A; Juanpere N; de Muga S; Lorenzo M; Salido M; Fumadó L; Serrano L; Cecchini L; Serrano S; Lloreta J
    Prostate; 2016 Jun; 76(9):854-65. PubMed ID: 26959281
    [TBL] [Abstract][Full Text] [Related]  

  • 60. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion.
    Perner S; Mosquera JM; Demichelis F; Hofer MD; Paris PL; Simko J; Collins C; Bismar TA; Chinnaiyan AM; De Marzo AM; Rubin MA
    Am J Surg Pathol; 2007 Jun; 31(6):882-8. PubMed ID: 17527075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.